Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Eur Radiol. 2023 Apr 26;33(10):7284–7293. doi: 10.1007/s00330-023-09658-1

Fig. 5.

Fig. 5

Overall survival (OS) of patients according to the tumor burden changes based on the 8-week landmark analyses. A In 124 patients after excluding 9 patients with OS of less than 8 weeks, OS was significantly longer in 95 patients whose tumor burden stayed below the baseline burden (< 0% increase) during the first 8 weeks of therapy than in 29 patients who had ≥ 0% increase in tumor burden by 8 weeks of therapy (median OS: with 24.9 vs. 7.6 months, HR = 0.36, p < 0.001). B In 99 patients who had the first follow-up CT within 8 weeks, 70 patients whose tumor burden stayed below the baseline burden (< 0% increase) during the first 8 weeks of therapy had significantly longer OS compared to 29 patients who had ≥ 0% increase by 8 weeks (median OS: 26.8 vs. 7.6 months, respectively, HR = 0.36, p < 0.001)